Expert Review of Anticancer Therapy, Год журнала: 2024, Номер unknown
Опубликована: Дек. 27, 2024
Introduction The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration evaluation.
Язык: Английский
Clinical Lymphoma Myeloma & Leukemia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Expert Opinion on Biological Therapy, Год журнала: 2025, Номер unknown
Опубликована: Март 19, 2025
Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) have a poor median survival rate when treated traditional salvage therapies. Bispecific antibodies (BsAbs) are an emerging class of 'off-the-shelf' immunotherapies that show promising efficacy in this population. Odronextamab is CD20×CD3 targeting bispecific antibody being investigated multiple subtypes B-NHL. This article describes the development odronextamab from pre-clinical work through to ongoing clinical trials The structure, safety, and administration discussed. Studies were selected for inclusion by performing search PubMed, EMBASE, Cochrane Library relevant conference abstracts 2014 2024. clinicaltrials.gov website reference lists included studies also reviewed. has demonstrated manageable safety low rates immune effector cell-associated neurotoxicity syndrome ;(ICANS) high response rare aggressive B-NHL particularly noteworthy. High severe infections remain challenge BsAbs, further prophylactic efforts required reduce risk. Clinical combination therapies improve utility BsAb across wider range settings
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(7), С. 1153 - 1153
Опубликована: Март 29, 2025
The introduction of bispecific antibodies (BsAbs) has led to significant improvements in survival for patients with relapsed and refractory B-cell lymphomas. Despite these advances, there remains a number who experience disease progression after novel therapies. Predicting which may respond certain treatments the durability their responses challenging. Measurable residual (MRD) become easier detect quantify through use genomic next-generation sequencing tools been studied as possible biomarker predict long-term outcomes risk-stratify BsAb therapy several lymphoma subtypes. Here, we review recent data demonstrating that MRD negativity is associated radiographic response improved progression-free survival. Because heterogeneity assay choice, assessment timing, technical parameters, further work needed before testing ready be incorporated into clinical practice context treatment
Язык: Английский
Процитировано
0
American Society of Clinical Oncology Educational Book, Год журнала: 2025, Номер 45(3)
Опубликована: Апрель 28, 2025
Antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric antigen receptor (CAR) are widely used standard-of-care therapies have revolutionized the treatment of lymphoid plasma cell malignancies. With recent regulatory approvals, these poised to also revolutionize common solid tumors become a part everyday lexicon, ABCs, practicing oncologist. Drawing from experience in hematology, we review early, late, rare toxicities ADCs, BsAbs, CAR provide general principles for their management.
Язык: Английский
Процитировано
0
Im Focus Onkologie, Год журнала: 2024, Номер 27(5), С. 34 - 37
Опубликована: Окт. 1, 2024
Процитировано
0
Expert Opinion on Therapeutic Patents, Год журнала: 2024, Номер unknown
Опубликована: Окт. 26, 2024
CD38 and BCMA are proteins expressed at high levels in multiple myeloma cells, so they targets for the development of mono- or multispecific antibodies.
Язык: Английский
Процитировано
0
Expert Review of Anticancer Therapy, Год журнала: 2024, Номер unknown
Опубликована: Дек. 27, 2024
Introduction The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration evaluation.
Язык: Английский
Процитировано
0